Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients

The standard of care for glioblastoma (GB) is surgery followed by concurrent radiation therapy (RT) and temozolomide (TMZ) and then adjuvant TMZ. This regime is associated with increased survival but also increased occurrence of equivocal imaging findings, e.g., tumor progression (TP) versus treatm...

Full description

Bibliographic Details
Main Authors: Cameron J. Koch, Robert A. Lustig, Xiang-Yang Yang, Walter T. Jenkins, Ronald L. Wolf, Maria Martinez-Lage, Arati Desai, Dewight Williams, Sydney M. Evans
Format: Article
Language:English
Published: Elsevier 2014-12-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S193652331400117X
id doaj-67db5518250f4c009e1718e201a41d9a
record_format Article
spelling doaj-67db5518250f4c009e1718e201a41d9a2020-11-24T21:31:38ZengElsevierTranslational Oncology1936-52331944-71242014-12-017675275810.1016/j.tranon.2014.10.004Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma PatientsCameron J. Koch0Robert A. Lustig1Xiang-Yang Yang2Walter T. Jenkins3Ronald L. Wolf4Maria Martinez-Lage5Arati Desai6Dewight Williams7Sydney M. Evans8Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA The standard of care for glioblastoma (GB) is surgery followed by concurrent radiation therapy (RT) and temozolomide (TMZ) and then adjuvant TMZ. This regime is associated with increased survival but also increased occurrence of equivocal imaging findings, e.g., tumor progression (TP) versus treatment effect (TE), which is also referred to as pseudoprogression (PsP). Equivocal findings make decisions regarding further treatment difficult and often delayed. Because none of the current imaging assays have proven sensitive and specific for differentiation of TP versus TE/PsP, we investigated whether blood-derived microvesicles (MVs) would be a relevant assay. METHODS: 2.8 ml of citrated blood was collected from patients with GB at the time of their RT simulation, at the end of chemoradiation therapy (CRT), and multiple times following treatment. MVs were collected following multiple centrifugations (300g, 2500g, and 15,000g). The pellet from the final spin was analyzed using flow cytometry. A diameter of approximately 300 nm or greater and Pacific Blue–labeled Annexin V positivity were used to identify the MVs reported herein. RESULTS: We analyzed 19 blood samples from 11 patients with GB. MV counts in the patients with stable disease or TE/PsP were significantly lower than patients who developed TP (P = .014). CONCLUSION: These preliminary data suggest that blood analysis for MVs from GB patients receiving CRT may be useful to distinguish TE/PsP from TP. MVs may add clarity to standard imaging for decision making in patients with equivocal imaging findings. http://www.sciencedirect.com/science/article/pii/S193652331400117X
collection DOAJ
language English
format Article
sources DOAJ
author Cameron J. Koch
Robert A. Lustig
Xiang-Yang Yang
Walter T. Jenkins
Ronald L. Wolf
Maria Martinez-Lage
Arati Desai
Dewight Williams
Sydney M. Evans
spellingShingle Cameron J. Koch
Robert A. Lustig
Xiang-Yang Yang
Walter T. Jenkins
Ronald L. Wolf
Maria Martinez-Lage
Arati Desai
Dewight Williams
Sydney M. Evans
Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients
Translational Oncology
author_facet Cameron J. Koch
Robert A. Lustig
Xiang-Yang Yang
Walter T. Jenkins
Ronald L. Wolf
Maria Martinez-Lage
Arati Desai
Dewight Williams
Sydney M. Evans
author_sort Cameron J. Koch
title Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients
title_short Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients
title_full Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients
title_fullStr Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients
title_full_unstemmed Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients
title_sort microvesicles as a biomarker for tumor progression versus treatment effect in radiation/temozolomide-treated glioblastoma patients
publisher Elsevier
series Translational Oncology
issn 1936-5233
1944-7124
publishDate 2014-12-01
description The standard of care for glioblastoma (GB) is surgery followed by concurrent radiation therapy (RT) and temozolomide (TMZ) and then adjuvant TMZ. This regime is associated with increased survival but also increased occurrence of equivocal imaging findings, e.g., tumor progression (TP) versus treatment effect (TE), which is also referred to as pseudoprogression (PsP). Equivocal findings make decisions regarding further treatment difficult and often delayed. Because none of the current imaging assays have proven sensitive and specific for differentiation of TP versus TE/PsP, we investigated whether blood-derived microvesicles (MVs) would be a relevant assay. METHODS: 2.8 ml of citrated blood was collected from patients with GB at the time of their RT simulation, at the end of chemoradiation therapy (CRT), and multiple times following treatment. MVs were collected following multiple centrifugations (300g, 2500g, and 15,000g). The pellet from the final spin was analyzed using flow cytometry. A diameter of approximately 300 nm or greater and Pacific Blue–labeled Annexin V positivity were used to identify the MVs reported herein. RESULTS: We analyzed 19 blood samples from 11 patients with GB. MV counts in the patients with stable disease or TE/PsP were significantly lower than patients who developed TP (P = .014). CONCLUSION: These preliminary data suggest that blood analysis for MVs from GB patients receiving CRT may be useful to distinguish TE/PsP from TP. MVs may add clarity to standard imaging for decision making in patients with equivocal imaging findings.
url http://www.sciencedirect.com/science/article/pii/S193652331400117X
work_keys_str_mv AT cameronjkoch microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients
AT robertalustig microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients
AT xiangyangyang microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients
AT waltertjenkins microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients
AT ronaldlwolf microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients
AT mariamartinezlage microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients
AT aratidesai microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients
AT dewightwilliams microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients
AT sydneymevans microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients
_version_ 1725960640013533184